UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2020 

Commission File Number: 001-31995

 

MEDICURE INC.

(Translation of registrant's name into English)

 

2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes o No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.

 

 

 

   
 

 


 

EXHIBIT LIST

Exhibit Title
   
99.1 News Release dated December 2, 2020 - Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.

 

 

 

 

   
 

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Medicure Inc.
  (Registrant)
   
     
Date: December 2, 2020 By: /s/ Dr. Albert D. Friesen                           
  Dr. Albert D. Friesen
  Title: CEO

 

 



Exhibit 99.1

 

 

 

Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.

NEW INVESTOR SLIDE PRESENTATION AVAILABLE AT WWW.MEDICURE.COM/INVESTORS

WINNIPEG, MB, Dec. 2, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that it has retained the services of Renmark Financial Communications Inc. ("Renmark") to conduct investor relations activities.  Additionally, the Company's website, www.medicure.com/investors, has been updated with a revised investor slide presentation.

"We are pleased to engage Renmark for investor relations activities. In relation to these activities, we have updated the investor presentation available on our website. We look forward to working with Renmark to enhance communication with a wider shareholder base and share the exciting developments at Medicure," stated Dr. Albert Friesen PhD, Chief Executive Officer of the Company and Chair of its Board of Directors.

In consideration of the services to be provided, the fees incurred by Medicure will be cash consideration of $5,000 per month, starting December 1, 2020 and ending on April 30, 2021.

Renmark does not have any interest, directly or indirectly, in Medicure or its securities, or any right or intent to acquire such an interest.

About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAGTM (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com. For additional information about ZYPITAMAGTM, refer to the full Prescribing Information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content:http://www.prnewswire.com/news-releases/medicure-retains-investor-relations-firm-renmark-financial-communications-inc-301183624.html

SOURCE Medicure Inc.

 

View original content: http://www.newswire.ca/en/releases/archive/December2020/02/c6691.html

%CIK: 0001133519

For further information: James Kinley: info@medicure.com, Chief Financial Officer, Tel. 888-435-2220, www.medicure.com; Renmark Financial Communications Inc., Daniel Gordon, dgordon@renmarkfinancial.com, Tel: (416) 644-2020 or (212) 812-7680, www.renmarkfinancial.com

CO: Medicure Inc.

CNW 09:00e 02-DEC-20



This regulatory filing also includes additional resources:
ex991.pdf